US Initiates Investigation into German Drug Pricing

The U.S. government has initiated an investigation into Germany's pharmaceutical pricing practices, citing concerns over alleged discrimination against American companies. The Office of the U.S. Trade Representative (USTR) announced the probe, which is being conducted under Section 301 of the Trade Act of 1974, a provision allowing the U.S. to take action against unfair trade practices.

The investigation centers on claims that Germany's price regulations for pharmaceuticals disadvantage U.S. drug manufacturers and result in the United States bearing an excessive share of global research and development costs for new medicines. The USTR is soliciting public comments on the matter and will hold a hearing in September. Potential outcomes could include the imposition of new tariffs or other trade restrictions on German goods.

U.S. Trade Representative Jamieson Greer stated that Germany's alleged "persistent underpayment" for innovative medicines forces the United States to shoulder a disproportionate burden of global R&D expenses. The U.S. administration expressed particular concern over reports of planned legislative changes in Germany that could further limit spending on innovative pharmaceuticals.

This investigation aligns with a broader U.S. trade policy aimed at addressing trade imbalances and encouraging pharmaceutical companies to increase investment and production within the United States. The U.S. has previously sought to influence global drug prices through various mechanisms, including its "Most Favored Nation" pricing strategy.